Analyst Reports
-
Kicking off FY25 with Important Trial Fully Recruited, $5.0m Capital Raise
-
MST Access: More shots on goal – new blood cancer indication for SNT-5505
-
MST Access: 1Q: Refocused Business Cutting Expenses, Progressing Trials
-
Bioshares: Pharmaxis – meaningful impact on bone marrow in myelofibrosis study
-
Taylor Collison: Progressing to next stage in scarring and myelofibrosis
-
Bioshares: Mixed results from Pharmaxis’ scar treatment study
-
MST Access: Pleasing results from established scars, phase 1c – more to come
-
MST Access: 3Q: cash balance comfortable as key trials proceed in tandem
-
MST Access: Useful FDA feedback paves way for new arm of lead clinical trial
-
MST Access: Raising PXS-5505 profile in new indication, synergies with SOC
-
MST Access: 2QFY23 – news flow plentiful in 2023 with data readouts from two major trials